PURPOSE: Cannabinoid subtype 1 (CB(1)) receptors are found in nearly every organ in the body, may be involved in several neuropsychiatric and metabolic disorders, and are therefore an active target for pharmacotherapy and biomarker development. We recently reported brain imaging of CB(1) receptors with two PET radioligands: (11)C-MePPEP and (18)F-FMPEP-d (2). Here we describe the biodistribution and dosimetry estimates for these two radioligands. METHODS: Seven healthy subjects (four men and three women) underwent whole-body PET scans for 120 min after injection with (11)C-MePPEP. Another seven healthy subjects (two men and five women) underwent whole-body PET scans for 300 min after injection with (18)F-FMPEP-d (2). Residence times were acquired from regions of interest drawn on tomographic images of visually identifiable organs for both radioligands and from radioactivity excreted in urine for (18)F-FMPEP-d (2). RESULTS: The effective doses of (11)C-MePPEP and (18)F-FMPEP-d (2) are 4.6 and 19.7 microSv/MBq, respectively. Both radioligands demonstrated high uptake of radioactivity in liver, lung, and brain shortly after injection and accumulated radioactivity in bone marrow towards the end of the scan. After injection of (11)C-MePPEP, radioactivity apparently underwent hepatobiliary excretion only, while radioactivity from (18)F-FMPEP-d (2) showed both hepatobiliary and urinary excretion. CONCLUSION: (11)C-MePPEP and (18)F-FMPEP-d (2) yield an effective dose similar to other PET radioligands labeled with either (11)C or (18)F. The high uptake in brain confirms the utility of these two radioligands to image CB(1) receptors in brain, and both may also be useful to image CB(1) receptors in the periphery.
PURPOSE: Cannabinoid subtype 1 (CB(1)) receptors are found in nearly every organ in the body, may be involved in several neuropsychiatric and metabolic disorders, and are therefore an active target for pharmacotherapy and biomarker development. We recently reported brain imaging of CB(1) receptors with two PET radioligands: (11)C-MePPEP and (18)F-FMPEP-d (2). Here we describe the biodistribution and dosimetry estimates for these two radioligands. METHODS: Seven healthy subjects (four men and three women) underwent whole-body PET scans for 120 min after injection with (11)C-MePPEP. Another seven healthy subjects (two men and five women) underwent whole-body PET scans for 300 min after injection with (18)F-FMPEP-d (2). Residence times were acquired from regions of interest drawn on tomographic images of visually identifiable organs for both radioligands and from radioactivity excreted in urine for (18)F-FMPEP-d (2). RESULTS: The effective doses of (11)C-MePPEP and (18)F-FMPEP-d (2) are 4.6 and 19.7 microSv/MBq, respectively. Both radioligands demonstrated high uptake of radioactivity in liver, lung, and brain shortly after injection and accumulated radioactivity in bone marrow towards the end of the scan. After injection of (11)C-MePPEP, radioactivity apparently underwent hepatobiliary excretion only, while radioactivity from (18)F-FMPEP-d (2) showed both hepatobiliary and urinary excretion. CONCLUSION:(11)C-MePPEP and (18)F-FMPEP-d (2) yield an effective dose similar to other PET radioligands labeled with either (11)C or (18)F. The high uptake in brain confirms the utility of these two radioligands to image CB(1) receptors in brain, and both may also be useful to image CB(1) receptors in the periphery.
Authors: S Galiègue; S Mary; J Marchand; D Dussossoy; D Carrière; P Carayon; M Bouaboula; D Shire; G Le Fur; P Casellas Journal: Eur J Biochem Date: 1995-08-15
Authors: George Kunos; Douglas Osei-Hyiaman; Sándor Bátkai; Keith A Sharkey; Alexandros Makriyannis Journal: Trends Pharmacol Sci Date: 2008-11-29 Impact factor: 14.819
Authors: Hubert Vesselle; John Grierson; Lanell M Peterson; Mark Muzi; David A Mankoff; Kenneth A Krohn Journal: J Nucl Med Date: 2003-09 Impact factor: 10.057
Authors: Koen Van Laere; Rawaha U Ahmad; Hendra Hudyana; Sofie Celen; Kristof Dubois; Mark E Schmidt; Guy Bormans; Michel Koole Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-16 Impact factor: 9.236
Authors: Szabolcs Farkas; Katalin Nagy; Miklós Palkovits; Gábor G Kovács; Zhisheng Jia; Sean Donohue; Vic Pike; Christer Halldin; Domokos Máthé; Tibor Harkany; Balázs Gulyás; László Csiba Journal: Neurochem Int Date: 2011-12-28 Impact factor: 3.921
Authors: Domokos Máthé; Ildikó Horváth; Krisztián Szigeti; Sean R Donohue; Victor W Pike; Zisheng Jia; Catherine Ledent; Miklós Palkovits; Tamás F Freund; Christer Halldin; Balázs Gulyás Journal: Brain Res Bull Date: 2013-01-11 Impact factor: 4.077
Authors: Kimberly J Jenko; Jussi Hirvonen; Ioline D Henter; Kacey B Anderson; Sami S Zoghbi; Thomas M Hyde; Amy Deep-Soboslay; Robert B Innis; Joel E Kleinman Journal: Schizophr Res Date: 2012-08-19 Impact factor: 4.939
Authors: Kimy M Emonds; Michel Koole; Cindy Casteels; Laura Van den Bergh; Guy M Bormans; Filip Claus; Liesbeth De Wever; Evelyne Lerut; Hendrik Van Poppel; Steven Joniau; Herlinde Dumez; Karin Haustermans; Luc Mortelmans; Karolien Goffin; Koen Van Laere; Christophe M Deroose; Felix M Mottaghy Journal: EJNMMI Res Date: 2013-08-02 Impact factor: 3.138
Authors: Daniela A Riaño Barros; Colm J McGinnity; Lula Rosso; Rolf A Heckemann; Oliver D Howes; David J Brooks; John S Duncan; Federico E Turkheimer; Matthias J Koepp; Alexander Hammers Journal: Neuroimage Date: 2014-04-13 Impact factor: 6.556